Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis We assessed the effects of vildagliptin, a novel dipeptidyl peptidase IV inhibitor, on postprandial lipid and lipoprotein metabolism in patients with type 2 diabetes.Subjects, materials and methods This was a single-centre, randomised, double-blind study in drug-naive patients with type 2 diabetes. Patients received vildagliptin (50 mg twice daily, n=15) or placebo (n=16) for 4 weeks. Triglyceride, cholesterol, lipoprotein, glucose, insulin, glucagon and glucagon-like peptide-1 (GLP-1) responses to a fat-rich mixed meal were determined for 8 h postprandially before and after 4 weeks of treatment.Results Relative to placebo, 4 weeks of treatment with vildagliptin decreased the AUC(0-8h) for total trigyceride by 22+/-11% (p=0.037), the incremental AUC(0-8h) (IAUC(0-8h)) for total triglyceride by 85+/-47% (p=0.065), the AUC(0-8h) for chylomicron triglyceride by 65+/-19% (p=0.001) and the IAUC(0-8h) for chylomicron triglyceride by 91+/-28% (p=0.002). This was associated with a decrease in chylomicron apolipoprotein B-48 (AUC(0-8h), -1.0+/-0.5 mg l(-1) h, p=0.037) and chylomicron cholesterol (AUC(0-8h), -0.14+/-0.07 mmol l(-1) h, p=0.046). Consistent with previous studies, 4 weeks of treatment with vildagliptin also increased intact GLP-1, suppressed inappropriate glucagon secretion, decreased fasting and postprandial glucose, and decreased HbA(1c) from a baseline of 6.7% (change, -0.4+/-0.1%, p<0.001), all relative to placebo.Conclusions/interpretation Treatment with vildagliptin for 4 weeks improves postprandial plasma triglyceride and apolipoprotein B-48-containing triglyceride-rich lipoprotein particle metabolism after a fat-rich meal. The mechanisms underlying the effects of this dipeptidyl peptidase IV inhibitor on postprandial lipid metabolism remain to be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the glucose-lowering actions, GLP-1RA based therapies have been reported to improve both fasting and postprandial lipid profiles in patients with T2D, in particular triglyceride concentrations [104,147,153,176,177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [177]
Experimental — accuracy not yet measuredIn the citing paper
“Additionally, a four-week treatment with DPP-4 inhibitor vildagliptin was also found to induce reductions in the postprandial TG and apolipoprotein B-48 containing TG-rich lipoprotein particle metabolism after a fat meal [177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Self-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Self-citationOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Self-citationAhrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Self-citationType 2 Diabetes as a “Coronary Heart Disease Equivalent”
Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2901 · Cited by 452
Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
Self-citationMaggs, D. G., Buchanan, T. A., Burant, C. F., Cline, G., Gumbiner, B., Hsueh, W. A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J. M., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00002 · Cited by 286
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · cited 3×
“This situation contrasts with the recent finding in healthy volunteers that exogenous GLP1 infusion (which increased plasma levels >10-fold) eliminated the postprandial increase in TGs [27].”
ResultInfluential
Cited by
Items 201–300 of 336
An Updated Perspective on the Dual-Track Model of Enterocyte Fat Metabolism
Cook, J. R., Kohan, A. B., & Haeusler, R. A. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100278 · Cited by 15
Blüher, M., Schweizer, A., Bader, G., & Foley, J. E. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s73608 · Cited by 15
Self-citationVed, P., & Shah, S. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94258 · Cited by 15
Diabetes medications and cardiovascular outcome trials: Lessons learned
Patel, K. V., Rocha, N. D. A., & McGuire, D. K. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84gr.17006 · Cited by 14
Onoue, T., Goto, M., Wada, E., Furukawa, M., Okuji, T., Okada, N., Kobayashi, T., Iwama, S., Sugiyama, M., Tsunekawa, T., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228004 · Cited by 14
Potential cardioprotective action of GLP-1: from bench to bedside
Aronis, K. N., Tsoukas, M. A., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.009 · Cited by 14
Doesch, A. O., Gueler, I., Mueller, S., Helmschrott, M., Oeing, C. U., Frankenstein, Gleissner, Ruhparwar, Ehlermann, Dengler, et al. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s43092 · Cited by 19
Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach
Dai, Y., Dai, D., Mercanti, F., Ding, Z., Wang, X., & Mehta, J. L. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0496-4 · Cited by 15
Davidson, M. H. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2756 · Cited by 13
Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?
Strain, W. D., & Smith, C. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0165-z · Cited by 15
Chen, K., Tiejun, Z., Wang, J., & Mei, Q. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0010 · Cited by 15
Glucagon-Like Peptide-1 and its Cardiovascular Effects
Heo, K., Fujiwara, K., & Abe, J. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0265-9 · Cited by 15
Tanimura‐Inagaki, K., Nagao, M., Harada, T., Sugihara, H., Moritani, S., Sasaki, J., Kono, S., & Oikawa, S. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108119 · Cited by 17
Varin, E. M., Hanson, A. A., Beaudry, J. L., Nguyen, M.-A., Cao, X., Baggio, L. L., Mulvihill, E. E., & Drucker, D. J. (2020) · JCI Insight · doi:10.1172/jci.insight.140418 · Cited by 15
Elrishi, M., Khunti, K., Jarvis, J., & Davies, M. (2007) · Practical Diabetes · doi:10.1002/pdi.1181 · Cited by 15
Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
Foley, J. E. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00780 · Cited by 13
Self-citationHissa, M. R. N., Cavalcante, L. L. A., Guimarães, S. B., & Hissa, M. N. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0058-8 · Cited by 14
High Risk of Lipoprotein Dysfunction in Type 2 Diabetes Mellitus
Carmena, R. (2008) · Revista Española de Cardiología · Cited by 18
Kurozumi, A., Okada, Y., Arao, T., Kobayashi, T., Masuda, D., Yamashita, S., & Tanaka, Y. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12739 · Cited by 11
on behalf of the EpiDREAM and INTERHEART investigators, Bailey, S. D., Xie, C., Paré, G., Montpetit, A., Mohan, V., Yusuf, S., Gerstein, H. C., Engert, J. C., & Anand, S. S. (2013) · Diabetologia · doi:10.1007/s00125-013-3142-3 · Cited by 13
NOGUCHI, K., Hirota, M., Miyoshi, T., Tani, Y., Noda, Y., Ito, H., & Nanba, S. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.2051 · Cited by 12
Dhindsa, S., & Jialal, I. (2014) · Current Diabetes Reports · doi:10.1007/s11892-013-0463-z · Cited by 12
Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
Solun, B., Marcoviciu, D., & Dicker, D. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0382-2 · Cited by 13
Current Approaches in Diabetes Treatment and Other Strategies to Reach Normoglycemia
Sirhan, W., & Piran, R. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200716113813 · Cited by 13
Newly appreciated therapeutic effect of GLP-1 receptor agonists: Reduction in postprandial lipemia
Bandsma, R., & Lewis, G. F. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.033 · Cited by 11
Lipid Effects of Endocrine Medications
Mihailescu, D. V., Vora, A., & Mazzone, T. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0146-z · Cited by 13
The 6th Annual World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2009) · Diabetes Care · doi:10.2337/dc09-zb09 · Cited by 13
Ahn, C. H., Kim, E. K., Min, S. H., Oh, T. J., & Cho, Y. M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12831 · Cited by 13
Preinfalk, V., Kimmeswenger, I., Somoza, V., & Lieder, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30329 · Cited by 10
Haluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10
Matsuyama‐Yokono, A., Tahara, A., Nakano, R., Someya, Y., Hayakawa, M., & Shibasaki, M. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0348-x · Cited by 10
DPP-4 inhibitors and atherosclerosis: The promise
Jialal, I., & Bajaj, M. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.12.033 · Cited by 10
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes
Stein, S. A., Lamos, E. M., & Davis, S. N. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.889683 · Cited by 10
Okada, K., Yagyu, H., Kotani, K., Yamazaki, H., Ozaki, K., Takahashi, M., Nagashima, S., Osuga, J.-I., & Ishibashi, S. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0019 · Cited by 11
DPP-IV inhibitors: Beyond glycaemic control?
Kwok, A. J., Mashar, M., Khavandi, K., & Sabir, I. N. (2013) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2013.10.002 · Cited by 9
El-Kabbany, Z. A., Ismail, E. A. R., Hamed, E. T., & Elbarbary, N. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15958 · Cited by 9
Turan, B., Durak, A. T., Olğar, Y., & Tuncay, E. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04474-5 · Cited by 9
Riesgo elevado de disfunción lipoproteica en la diabetes mellitus tipo 2
Carmena, R. (2008) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(08)73551-9 · Cited by 17
Okajima, F., Emoto, N., Kato, K., & Sugihara, H. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.32409 · Cited by 9
Miranda, P. H. D. A., Lacerda, K. C. D., Araújo, C. M., Barichello, J. M., de Lima, W. G., & Costa, D. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-33727-x · Cited by 8
Oikawa, S. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.950 · Cited by 8
Translating science into clinical practice: focus on vildagliptin in combination with metformin
Barnett, A. H. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01030.x · Cited by 8
Postprandial triglyceride-rich lipoproteins in insulin resistance and Type 2 diabetes
Matikainen, N., & Taskinen, M. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.531 · Cited by 8
Self-citationÅhrén, B. (2009) · Insulin · doi:10.1016/s1557-0843(09)80004-3 · Cited by 7
Shoier, N. O., Ghareib, S. A., Kothayer, H., Alsemeh, A. E., & El-Sayed, S. S. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03439-3 · Cited by 7
The effect of antidiabetic drugs on genes regulating lipid metabolism
TOMKIN, G. H. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32831ac56c · Cited by 6
Unintended positive and negative effects of drugs on lipoproteins
Siahmansur, T. J., Schofield, J. D., Azmi, S., Liu, Y., Durrington, P. N., & Soran, H. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000198 · Cited by 8
A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes
Cornell, S. A. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12040 · Cited by 6
Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors
Cameron-Vendrig, A., Mundil, D., & Husain, M. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0408-2 · Cited by 5
Majeed, S. A., Hadi, N. R., Al-Mudhafar, A. M., & Al-Janabi, H. A. (2013) · SAGE Open Medicine · doi:10.1177/2050312113499912 · Cited by 8
Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
Vildagliptin: novel pharmacological approach to treat Type 2 diabetes
Åhrén, B. (2008) · Therapy · doi:10.2217/14750708.5.1.79 · Cited by 6
Desai, G. S., Desai, S., Gavaskar, R. S., Mulabagal, V., Wu, Y., & Mathews, S. T. (2015) · Phytotherapy Research · doi:10.1002/ptr.5394 · Cited by 5
Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism
Taskinen, M., Matikainen, N., Björnson, E., Söderlund, S., Ainola, M., Hakkarainen, A., Lundbom, N. M. I., Sihlbom, C., Thorsell, A., Andersson, L., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1187 · Cited by 4
Self-citationGuo, J., Xu, F., Xie, Y., Chen, B., Wang, Y., Nie, W., Zhou, K., Zhou, H. M., & Xu, B. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202101020 · Cited by 4
Vildagliptin for the treatment of diabetes
Samraj, G. P. N. (2011) · Therapy · doi:10.2217/thy.11.75 · Cited by 4
Ahmed, H. A., May, D. W., Fagan, S. C., & Segar, L. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1547 · Cited by 4
Son, C., Kasahara, M., Tanaka, T., Satoh‐Asahara, N., Kusakabe, T., Nishimura, K., Miyamoto, Y., Kasama, S., & Hosoda, K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00717-9 · Cited by 4
Zhao, L., Meng, J., Li, J., Cong, H., Liu, C., Yang, Y., Wu, Y., & Liu, X. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf209 · Cited by 4
Tolba, M. K. A., Elkhashab, K., & Said, A. S. A. (2016) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2017v9i1.15496 · Cited by 2
Comparison of DPP-4 Inhibitors
Kim, N. H., & Kim, S. G. (2013) · Journal of Korean Diabetes · doi:10.4093/jkd.2013.14.3.111 · Cited by 3
Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes
Åhrén, B. (2012) · Diabetes Management · doi:10.2217/dmt.12.40 · Cited by 3
Aramaki, M. (2013) · Clinical Lipidology · doi:10.2217/clp.13.46 · Cited by 3
Efficacy and safety of Vildagliptin in the management of type 2 Diabetes Mellitus
Iftekar, H., Kalaiselvan, & Gyanendra, N. S. (2012) · Indian Journal of Pharmacy Practice · Cited by 3
Lipid Lowering Effect of Anti Diabetic Agents-Recent Research
Pavithra, N., & Chaitanya, M. (2015) · International journal of pharma research and review · Cited by 6
(2020) · International Journal of Veterinary Science · doi:10.37422/ijvs/20.028 · Cited by 4
Gliptin Therapies for Inhibiting Dipeptidyl Peptidase-4 in Type 2 Diabetes
Green, B. D., Bailey, C. J., & Flatt, P. R. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2010.06.02.19 · Cited by 4
Higgins, V., & Adeli, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65897-x · Cited by 3
Jawad, A. N., Kadhim, K. A., Alzajaji, Q. B., & Al-Neshmi, H. (2024) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v24i3.1082 · Cited by 2
Arca, M., Björnson, E., D’Erasmo, L., Costanzo, A. D., Bini, S., Minicocci, I., Tramontano, D., Covino, S., Ciarlo, G., Lombardi, M., et al. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70124 · Cited by 2
Self-citationDipeptidyl Peptidase Inhibitors: A New Step Towards Normoglycemia
Fredenrich, A., Palle, S., & Canivet, B. (2009) · The Open Endocrinology Journal · doi:10.2174/1874216500903010016 · Cited by 2
Otterbeck, P. E., & Banerji, M. A. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.6 · Cited by 1
Pleiotropic effects of incretins and antidiabetics with incretine mechanism
Winkler, G. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29553 · Cited by 2
Role of enterocytes in dyslipidemia of insulin-resistant states
Nogueira, J. P., & Brites, F. D. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.06.011 · Cited by 2
Jindal, A., Kaur, R., Jindal, M., Ganga, M., & Dental, S. (2015) · Cited by 2
Vildagliptin An Oral Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes
Standl, E., Füchtenbusch, M., & Hummel, M. (2006) · US Endocrinology · doi:10.17925/use.2006.00.02.1m · Cited by 2
Raghavan, V., Lahiri, A., Akul, S. K., Goswami, U., Gupta, C. N., & Sen, S. (2019) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20191163 · Cited by 2
Glucagon and the Glucagon-Like Peptides
Drucker, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00034-2 · Cited by 2
HEBAT ALLAH M. MAHMOUD, M. S. ;. F. A. M., HASHEM, M. D. H. H. A. G., & Mahmoud, H. (2018) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2018.55786 · Cited by 2
Можливості вілдагліптину в оптимальному контролі цукрового діабету 2-го типу
Pankiv, V. І. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.6.2019.185411 · Cited by 2
AKTAŞ, A., & Ozan, Z. T. (2020) · Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi · doi:10.7197/cmj.835387 · Cited by 2
Mahboub, B. M., El-Haggar, S. M., Abdelraouf, Y. M., & El-Azab, G. A. (2019) · doi:10.35248/2155-6156.19.10.834 · Cited by 1
Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes
Rizzo, M., TOMKIN, G. H., Angelo, M. P., Pepe, I., Maria, R. V., Rosa, S. D., Giovam, B. R., & Fede, G. D. (2011) · Clinical Lipidology · doi:10.2217/clp.11.46 · Cited by 1
Okayama, N., Imaeda, K., Kato, T., Iwase, S., Ohguchi, H., Joh, T., Hayashi, Y., Akao, M., Ogawa, K., Hachiya, M., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0113-3 · Cited by 1
Milan Meloun, A., Ferenčíková, Z., Niesnerová, I., & Pekárek, T. (2013) · Open Chemistry · doi:10.2478/s11532-013-0244-1 · Cited by 1
Rôle de l’entérocyte dans les anomalies lipidiques de l’insulinorésistance
Valéro, R., Maraninchi, M., & Nogueira, J. P. (2009) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(09)73619-3 · Cited by 3
Rol del enterocito en la dislipemia de la resistencia insulínica
Nogueira, J. P., & Brites, F. D. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.06.009 · Cited by 3
Jialal, I., & Dhindsa, S. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.1500 · Cited by 1
Basile, J. (2016) · Hospital Practice · doi:10.1080/21548331.2016.1141656 · Cited by 2
Vildagliptin improves glycemic control in type 2 diabetes patients undergoing hemodialysis
Ishioka, K., Furuya, R., Iwagami, M., Tsutsumi, D., Mochida, Y., Oka, M., Maesato, K., Moriya, H., Ohtake, T., Hidaka, S., et al. (2013) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.46.103 · Cited by 1
DPP-4-Hemmer und GLP-1-Rezeptor-Agonisten: Kardiovaskuläre Effekte
Nauck, M. A., Aziz, M. S. A. E., & Meier, J. J. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0083-8 · Cited by 1
CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
Petunina, N. A., Валерьевна, Г. Е., & Potapova, S. A. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-3-32-37 · Cited by 1
Yilmaz, B. A., & Törüner, F. B. (2013) · CRC Press eBooks · doi:10.1201/b14907-9 · Cited by 1
Kurozumi, A., Okada, Y., Satoh, H., Inoue, I., Chimori, H., Akita, E., Shiraiwa, T., Fujitani, Y., Mita, T., Gosho, M., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej17-0386 · Cited by 1
Mulder, D. J., Heerspink, H. J. L., & Lefrandt, J. D. (2012) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-012-0002-6
Nogueira, K. C. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2012.tde-27072012-155318
GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Burcelin, R., Cabou, C., Magnan, C., & Gourdy, P. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch11
Diabetes Mellitus: Dipeptidyl Peptidase 4 Inhibitors and Cardiovascular Outcomes
Pastromas, S. (2014) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v9i2.601
Tushuizen, M. E. (2012) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Juurinen, L. (2014) · Helda - University of Helsinki Institutional Repository
Metadata
- Authors
- Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R.
- Affiliations
- Helsinki University Hospital (FI)
- Novartis (Switzerland) (CH)
- Corresponding author
- Taskinen, M.-R.
- Venue
- Diabetologia
- Published
- 2006-07-01
- Volume
- 49
- Issue
- 9
- Pages
- 2049-2057
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2152978153
- Cited by
- 336
- References
- 29
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 8 · 2023: 2 · 2022: 8 · 2021: 5 · 2020: 13 · 2019: 11 · 2018: 10 · 2017: 15 · 2016: 24 · 2015: 23 · 2014: 34 · 2013: 38 · 2012: 29
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Funders
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- DPP-4 inhibitors, type 2 diabetes, postprandial lipemia, triglyceride-rich lipoproteins, chylomicrons, apolipoprotein B-48, glucagon-like peptide-1, glucagon secretion, postprandial lipoprotein metabolism
- MeSH terms
- Vildagliptin, Adamantane, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Humans, Insulin, Intestinal Mucosa, Intestines, Lipids, Lipoproteins, Male, Middle Aged, Nitriles, Pyrrolidines, Time Factors, Triglycerides, Treatment Outcome, Postprandial Period, Glucagon-Like Peptide 1, Apolipoprotein B-48, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.